Amyotrophic Lateral Sclerosis Treatment Market By Drugs (Riluzole, Edaravone, Others), By Type (Sporadic ALS, Familial ALS), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis an

Amyotrophic Lateral Sclerosis Treatment Market By Drugs (Riluzole, Edaravone, Others), By Type (Sporadic ALS, Familial ALS), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

The amyotrophic lateral sclerosis treatment market valued for $662.25 million in 2022 and is estimated to reach $1,038.94 million by 2032, exhibiting a CAGR of 4.6% from 2023 to 2032.

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. ALS causes these nerve cells to gradually break down and die, which results in the loss of muscle control and eventual paralysis. The symptoms of ALS typically begin with muscle weakness or stiffness, often in the hands or feet, and gradually spread to other parts of the body. Other symptoms include difficulty speaking, swallowing, or breathing, as well as muscle cramps and twitching. There is currently no cure for ALS, and treatment mainly focuses on managing symptoms and improving the quality of life for people with the disease.

Some of the drugs that are commonly used to treat amyotrophic lateral sclerosis include Riluzole, Edaravone, and Sodium phenylbutyrate and taurursodio. Riluzole works by reducing the release of glutamate, a neurotransmitter that damage motor neurons and Edaravone is a free radical scavenger that works by reducing oxidative stress in the body, which damage the motor neurons.

The major factors that drive the growth of the global amyotrophic lateral sclerosis treatment market include, increase in prevalence of amyotrophic lateral sclerosis, and rise in approval of new drugs and therapies for ALS. The incidence of ALS is expected to rise, as the global population ages, leading to a growth in demand for treatments and therapies that may help to manage the symptoms and slow the progression of the disease.

Another market driver is the growth in awareness and understanding of ALS among healthcare professionals, patients, and caregivers. There is a greater understanding of the underlying mechanisms of ALS and potential targets for treatment with more research being done on the disease and advances in medical technology. This has led to the development of new therapies, such as gene therapies and stem cell treatments, which are expected to drive market growth during the forecast period.

In addition, regulatory frameworks and reimbursement policies may also impact the market for ALS treatments. The approval of new drugs and therapies by regulatory bodies, such as the U.S. FDA, may drive market growth by providing patients with access to new and innovative treatments. For instance, increase in pipeline products such as Tofersen, ANX005 and others for treating an amyotrophic lateral sclerosis which is anticipated to provide lucrative opportunities to the market players. Reimbursement policies that provide coverage for these treatments can also help to expand the market by making them more accessible and affordable for patients.

However, limited understanding of the disease, stringent regulatory process for approving new treatments for ALS, which can delay the availability of new therapies for patients and higher treatment may restrict the market growth.  

The amyotrophic lateral sclerosis treatment market is segmented into drug, type, distribution channel, and region. On the basis of drug, the market is categorized into Riluzole, Edaravone, and others. On the basis of type, the market is bifurcated into sporadic ALS and familial ALS. On the basis of distribution channel, the market is classified into hospital pharmacies, online providers, and drug stores & retail pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Major key players that operate in the global amyotrophic lateral sclerosis treatment market are Aquestive Therapeutics, Inc., Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Viatris Inc., Amylyx Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Otsuka Pharmaceutical Co., Ltd., Covis Pharma GmbH, ITALFARMACO S.p.A., and Alkem Laboratories Ltd. Key players operating in the market have adopted product approval, agreement, and product launch as their key strategies to expand their product portfolio. For instance, in January 2023, Amylyx Pharmaceuticals, Inc. announced it has entered into an exclusive license and distribution agreement with Neopharm in which Neopharm is expected to commercialize to regulatory review and approval of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS) in Israel, Gaza, West Bank, and the Palestinian. 

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the amyotrophic lateral sclerosis treatment market analysis from 2022 to 2032 to identify the prevailing amyotrophic lateral sclerosis treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the amyotrophic lateral sclerosis treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global amyotrophic lateral sclerosis treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drugs

Riluzole
Edaravone
Others

By Type

Sporadic ALS
Familial ALS

By Distribution Channel

Hospital Pharmacies
Online Providers
Drug Stores and Retail Pharmacies

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Alkem Laboratories Ltd
Amylyx Pharmaceuticals, Inc.
Aquestive Therapeutics, Inc.
Covis Pharma GmbH
Glenmark Pharmaceuticals Limited
ITALFARMACO S.p.A.
Mitsubishi Chemical Group Corporation
Otsuka Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Viatris Inc.

Please Note: It will take 7-10 business days to complete the report upon order confirmation.